Dasatinib and chronic myeloid leukemia
Authors:
M. Doubek; D. Žáčková; J. Vorlíček; J. Mayer
Authors place of work:
Interní hematologická klinika LF MU a FN Brno
Published in the journal:
Reviz. posud. Lék., 10, 2007, č. 2, s. 60-64
Category:
News
Summary
BCR-ABL, a constitutively active tyrosine kinase, causes chronic myeloid leukaemia (CML). Rational development of drugs targeting BCR-ABL has significantly improved the treatment of CML. Imatinib (a BCR-ABL tyrosine kinase inhibitor) produces haematological and cytogenetic remissions across all phases of CML and is the present standard of care. However, imatinib resistance occurs in a significant proportion of patients and mechanisms of resistance include BCR-ABL mutations and activation of alternate oncogenic pathways. Dasatinib is a novel, potent, multi-targeted oral kinase inhibitor. Preclinical and clinical investigations demonstrate that dasatinib effectively overcomes imatinib resistance and has further improved the treatment of CML.
Key words:
chronic myeloid leukemia – dasatinib – imatinib – transplantation
Zdroje
1. Baccarani, M., Kantarjian, H., Apperley, J. et al. Dasatinib (SPRYCEL®) induces durable cytogenetic responses in patients with CP-CML with resistance or intolerance to imatinib: updated results of the CA180-013 START-C phase II study. Blood, 2006, 108, abstract 164.
2. Baccarani, M., Saglio, G., Goldman, J. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood, 2006, 108, p. 1809–1820.
3. Cortes, J., Kim, D. W., Guilhot, F. et al. Dasatinib (SPRYCEL®) in Patients with Chronic Myelogenous Leukemia in Accelerated Phase that is Imatinib-resistant or -intolerant: Updated Results of the CA180-005 ‘START-A’ Phase II Study. Blood, 2006, 108, abstrakt 2160.
4. Cortes, J., Rousselot, P., Dong-Wook, K. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 2006, Blood First Edition Paper, prepublished online, DOI 10.1182/blood-2006-09-046888.
5. Das, J., Chen, P., Norris, D. et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[6-[4-(2-hydroxyphenyl)-1-piperazinyl)]-2-methyl-4-pyrimidinylamino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem., 2006, 49, p. 6819–6832.
6. Deininger, M., Buchdunger, E., Druker, B. J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 2005, 105, p. 2640–2653.
7. Doubek, M., Vítek, A., Mayer, J. Reduced-intensity allografting for chronic myeloid leukemia in the first chronic phase. Haematologica, 2004, 89, 1, ELT03.
8. Doubek, M., Žáčková, D., Mayer, J. Dasatinib. Remedia, 2007, 17, s. 59–63.
9. Druker, B. J., Guilhot, F., O’Brien, S. G. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 2006, 355, p. 2408–2417.
10. Druker, B. J., Sawyers, C. L., Kantarjian, H. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lym-phoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 2001, 344, p. 1038–1042.
11. Faber, E. Dasatinib. Farmakoterapie, 2006, 2, s. 135–137.
12. Faber, E. Imatinib. Farmakoterapie, 2005, 1, s. 233–238.
13. Faber, E. Imatinib (Glivec®) v léčbě nemocných s akcelerovanou fází chronické myeloidní leukemie – první zkušenosti. Trendy v medicíně, 2002, 4, s. 3–7.
14. Faber, E., Indák, K. Dasatinib. Farmakoterapie, 2007, 3, s. 135-140.
15. Goldman, J. M., Melo, J. V. Chronic myeloid leukemia – advances in biology and new approaches to treatment. N. Engl. J. Med., 2003, 349, s. 1451–1464.
16. Guilhot, F., Apperley, J., Kim, D. W. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or –intolerant chronic myeloid leukemia in accelerated phase. Blood, 2006, Blood First Edition Paper, prepublished online, DOI 10.1182/blood- -2006-09-046839.
17. Guilhot, F., Roy, L., Guilhot, J. et al. Retrospective comparison of imatinib versus interferon plus cytarabine for chronic myelogenous leukemia patients in chronic phase. Blood, 2005, 106, abstrakt 165.
18. Hehlmann, R. Current CML therapy: progress and dilemma. Leukemia, 2003, 17, p. 1010–1012.
19. Hochhaus, A., Kim, D. W., Rousselot, P. et al. Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study. Blood, 2006, 108, abstrakt 166.
20. Hochhaus, A., La Rosée, P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia, 2004, 18, p. 1313–1321.
21. Kantarjian, H. M., Cortes, J., O’Brien, S. et al. Imatinib mesylate (STI 571) therapy for Philadelphia chromosome – positive chronic myelogenous leukemia in blast phase. Blood, 2002, 99, p. 3547–3553.
22. Kantarjian, H., Ottmann, O., Pasquini, R. et al. Dasatinib (SPRYCEL®) 140 mg QD vs 70 mg BID in Advanced Phase CML (ABP-CML) or Ph(+) ALL Resistant or Intolerant to Imatinib – Results of the CA180-035 Study. Blood, 2006, 108, abstrakt 746.
23. Krejčí, M., Doubek, M., Brychtová, Y. et al. Is nonmyeloablative transplant sufficient to cure chronic myeloid leukemia? Haematologica, 2005, 90, Suppl. 2, abstrakt 0526.
24. Krejčí, M., Mayer, J., Doubek, M. et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant., 2006, 38, p. 483–491.
25. Lee, S. J., Anasseti, C., Kuntz, K. M. et al. The cost and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood, 1998, 92, p. 4047–4052.
26. Levitzki, A., Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science, 1995, 267, p. 1782–1788.
27. Martinelli, G., Hochhaus, A., Coutre, S. et al. Dasatinib (SPRYCEL®) Efficacy and Safety in Patients With Chronic Myelogenous Leukemia in Lymphoid or Myeloid Blast Phase with Imatinib Resistance or Intolerance. Blood, 2006, 108, abstrakt 745.
28. Mayer, J. Chronická myeloidní leukemie jako model moderní necytostatické léčby maligních chorob. Od Virchowa po STI 571. Vnitřní Lék., 2002, 48, s. 45–49.
29. Mayer, J., Krahulová, M., Kořístek, Z. et al. Alogenní transplantace periferních kmenových buněk po nemyeloablativním režimu. První zkušenosti. Čas. Lék. čes., 1999, 138, s. 624–627.
30. Naušová, J., Priwitzerová, M., Jarošová, M. et al. Chronická myeloidní leukemie – rezistence na imatinib mesylát (Glivec) – přehled literatury a vlastní zkušenosti. Čas. Lék. čes., 2006, 145, s. 377–382.
31. O’Brien, S. G., Guilhot, F., Larson, R. A. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 2003, 348, p. 994–1004.
32. O’Brien, S., Radich, J. P. (Eds.). NCCN Clinical Practice Guidelines in Oncology. Cronic Myelogenous Leukemia. In 2. 2007. National Comprehensive Cancer Network. www.nccn.org.
33. O’Hare, T., Walters, D. K., Stoftregen, E. P. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res., 2005, 65, p. 4500–4505.
34. Or, R., Shapira, M. Y., Resnick, I. et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood, 2003, 101, p. 441–445.
35. Quintas-Cardema, A., Kantarjian, H. M., Munden, R. et al. Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure. Blood, 2006, 108, abstrakt 2164.
36. Radich, J. P., Olavarria, E., Apperley, J. F. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol. Oncol. Clin. N. Am., 2004, 18, p. 685–702.
37. Shah, N., Pasquini, R., Rousselot, P. et al. Dasatinib (Sprycel) vs. escalated dose of imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib: results of the CA180-017 START-R randomized study. Blood, 2006, 108, abstrakt 167.
38. Shah, N. P., Tran, C., Lee, F. Y. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 2004, 305, p. 399–401.
39. Skrepnek, G. H., Ballard, E. E. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmaco-therapy, 2005, 25, p. 325–334.
40. Talpaz, M., Shah, N. P., Kantarjian, H. et al. Dasatinib in imatinib-resistant philadelphia chromosome-positive leukemias. N. Engl. J. Med., 2006, 354, p. 2531–2541.
Štítky
Medical assessment Occupational medicineČlánok vyšiel v časopise
Medical Revision
2007 Číslo 2
Najčítanejšie v tomto čísle
- Equity in health status and health services
- Pregnancy – disease or physiological state?
- Malignant tumors of head and neck – assessment problems
- Social care in health care facilities